Clinical trials: High-Risk Cancer
Brain and Central Nervous System Tumors
Taurolidine in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of taurolidine in treating patients who have recurrent or…
- Trial name
- NCT00022360
- Testing
- taurolidine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Skin Cancers
Defining the Role of Optical Super-high Magnification Dermoscopy in the Diagnosis of Skin Tumors
This is a prospective study aimed at evaluating the diagnostic accuracy (compared to histopathological diagnosis) and clinical utility of optical super-high magnification dermoscopy (OSHMD) in detecting and differentiating skin…
- Trial name
- OSHMD (NCT06908720)
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Ospedale San Raffaele
Metastasis From Malignant Melanoma of Skin (Diagnosis)
Irradiation of Melanoma in a Pulse
This is a single center phase I, first-in-human, dose escalation study of FLASH therapy in patients with metastases of melanoma.
- Trial name
- IMPulse (NCT04986696)
- Testing
- FLASH therapy
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Intrahepatic Cholangiocarcinoma, PD1 Antibody
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low…
- Conditions
- Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
- Trial name
- NCT04669496
- Testing
- Neoadjuvant treatment
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shanghai Zhongshan Hospital
Myocardial Injury After Noncardiac Surgery (MINS), Postoperative Complications
Prediction Model for MINS After Major Hepatobiliary Surgery
This multi-center, prospective observational study aims to develop and validate an interpretable prediction model for Myocardial Injury After Noncardiac Surgery (MINS) in patients undergoing major hepatobiliary surgery.
- Conditions
- Myocardial Injury After Noncardiac Surgery (MINS), Postoperative Complications, Liver Neoplasm, Hepatobiliary Diseases
- Trial name
- NCT07335042
- Testing
- Major Hepatobiliary Surgery
- Where
- 6 sites in China
- Volunteers
- 1,800 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Multiple Myeloma
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
The purpose of this study is to see whether combination of low dose lenalidomide(10mg)+ dexamethasone is equally effective in treating relapsed/refractory myeloma in the group of elderly patients and other patients at risk of…
- Trial name
- NCT00482261
- Testing
- Lenalidomide, dexamethasone, aspirin
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Neuroendocrine Tumors, Metastases, Neoplasm
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG) can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine tumors.
- Trial name
- NCT00037869
- Testing
- I-131 Metaiodobenzylguanidine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Mediastinal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Mediastinal Cancer, Metastatic Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00003941
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 222 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00003541
- Testing
- filgrastim, CHOP regimen, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma.
- Trial name
- NCT02805894
- Testing
- NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nanobiotix
Precancerous Condition, Stage 0 Melanoma
Lovastatin in Treating Patients At High Risk of Melanoma
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma.
- Conditions
- Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
- Trial name
- NCT00462280
- Testing
- lovastatin, biopsy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
The purpose of this study is to learn about the safety and effects of the study medicine (Disitamab Vedotin) in people with non-muscle invasive bladder cancer.
- Trial name
- HERO (NCT07207824)
- Testing
- Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
Brain and Central Nervous System Tumors, Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00002754
- Testing
- monoclonal antibody Me1-14 F(ab')2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Severe
Low-Sodium Diet for Postpartum Blood Pressure Control
The goal of this randomized controlled trial is to learn if a low-sodium diet improves postpartum blood pressure control in adults who were diagnosed with a late-onset hypertensive disorder of pregnancy.
- Conditions
- Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Severe, Pre-Eclampsia; Mild, Postpartum
- Trial name
- NCT07752056
- Testing
- Low Sodium Diet
- Volunteers
- 110 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Locally Recurrent Prostate Cancer
Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy
This purpose of this study is to evaluate the safety and effectiveness of a technique called focal high-dose-rate (HDR) brachytherapy as treatment for prostate cancer that has come back in the prostate after prior radiotherapy.
- Trial name
- F-Sharp (NCT03312972)
- Testing
- HDR Brachytherapy
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Loyola University
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT02392572
- Testing
- Akt/ERK Inhibitor ONC201, Venetoclax
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer
The goal of this clinical study is to evaluate the potential benefits of intensified surveillance versus standard surveillance in medium-risk and high-risk early breast cancer patients.
- Trial name
- SURVIVE (NCT05658172)
- Testing
- Determination of tumormarkers (CA27.29, CEA, CA125), Determination of CTC levels, Determination of ctDNA levels
- Where
- Germany
- Volunteers
- 3,500 people
- Sponsor
- Prof. Wolfgang Janni
Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
This phase II trial studies how well tislelizumab combined with DNA hypomethylation agent +/- CAG regimen (cytarabine, idarubicin / Aclarithromycin, rhG-CSF/ PEG-rhG-CSF) work in treating patients with high-risk acute myeloid…
- Conditions
- Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease
- Trial name
- NCT04541277
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Chinese PLA General Hospital
Breast Cancer
Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease
This study will evaluate the safety and feasibility of administering a peptide vaccine consisting of twelve different tumor-rejection antigens to patients with high risk (TxN2-3M0) or metastatic breast cancer with no evidence of…
- Trial name
- NCT00674791
- Testing
- OCPM Immunotherapeutic Vaccine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Duke University
Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.
- Trial name
- NCT07412613
- Testing
- Cadonilimab (AK104), Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Akeso
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.